NCT07573046 · NOT YET RECRUITING

Validation Study of the ExéSem Battery Designed to Differentiate the Contribution of Executive Functions in Semantic Disorders

This study is testing a new cognitive assessment tool called the ExéSem battery. Researchers want to know whether it can reliably tell apart two different causes of word-finding problems: one rooted in damaged semantic memory, the other in impaired executive control. It enrolls people with Alzheimer's disease, vascular cognitive impairment, a language disorder called semantic variant PPA, and healthy adults for comparison. There is no phase designation — this is a diagnostic validation study, not a drug trial.

Eligibility criteria

Inclusion Criteria:
* - Participants without cognitive impairment
* Participant aged 50 to 90 years (inclusive);
* Participant whose native language is French
* Participant affiliated with or entitled to a social security scheme;
* Participants who have been informed and have not objected.
* Participants with cognitive impairment
* Participant aged 50 to 90 years (inclusive);
* Participant whose native language is French
* Participant receiving memory care with a diagnosis of Alzheimer's disease, at the stage of minor or major neurocognitive impairment, according to the 2011 NIA-AA criteria (McKahn et al., 2011), or with a diagnosis of vascular neurocognitive impairment according to the VasCog-2-WSO diagnostic criteria (Sachdev et al., 2025), or with a diagnosis of primary progressive aphasia with semantic variant (Gorno-Tempini et al., 2011).
* Mini-Mental State Examination (MMSE) score ≥ 20/30, within the 6 months preceding enrollment;
* Participants affiliated with or entitled to a social security scheme;
* Participants who have been informed and have not objected.
Exclusion Criteria:
* - For all participants:
* Severe, progressive, or unstable medical conditions that may interfere with assessment variables (epilepsy, acute psychiatric or psychotic disorders, visual hallucinations, acute infection);
* Substance use that may affect cognitive performance;
* Deafness or blindness that may compromise the participant's assessment or participation in tasks and scales;
* Participants under guardianship, curatorship, or legal protection;
* Pregnant, postpartum, or breastfeeding women.
* Specifically for participants without cognitive impairment:
* Participants previously diagnosed with cognitive impairment.
* Specifically for participants with cognitive impairment:
* Severe behavioral and psychological symptoms that prevent task completion, as determined by the investigator.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-05-07

View full record on ClinicalTrials.gov

All APOE4 clinical trials